Cue Biopharma Q4 2024 net loss narrows to $9.5M; cash at $22.5M; pipeline pivots to autoimmune

Cue Biopharma, Inc.

2025-Q1 EPS reported -$0.17 vs consensus -$4.65 ▲ beat (+96.3%)

Net loss of $9.5M in Q4 2024 ($0.13/share) vs $13.4M in Q4 2023; full year net loss $40.7M.
Collaboration revenue $1.6M in Q4 vs $1.8M a year ago; full year rev $9.3M from Ono Pharma deal.
R&D spend cut to $7.2M (Q4) from $10.9M; cash and equivalents $22.5M as of Dec 31, 2024.
Regained worldwide rights to CUE-401 (autoimmune lead); prioritizing autoimmune over oncology.
Appointed Lucinda Warren (CBO), Dr. Daniel Baker (Interim CDO), Dr. Pasha Sarraf (Board).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.